TrialArthritis & rheumatology (Hoboken, N.J.)2026

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial.

Andrea Fava et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.